🚀 VC round data is live in beta, check it out!
Yantai Dongcheng Valuation Multiples
Discover revenue and EBITDA valuation multiples for Yantai Dongcheng and similar public comparables like Ardelyx, OneSource Specialty, Sawai Group Holdings, Biohaven and more.
Yantai Dongcheng Overview
About Yantai Dongcheng
Yantai Dongcheng Biochemicals Co Ltd is a biochemical analytical profile index (API) manufacturers in China. In addition, the company also focuses on the development of finished preparation which covers the therapeutic area of cardiovascular, oncology, orthopedics, and anti-infection. Its product offering includes heparin sodium, chondroitin sulfate, marine collagen, hyaluronic acid, glucosamine, heparinoids, and cytochrome C. The company's API products have been exported to more than fifty countries and regions, including the United States of America, Germany, Austria, and Japan.
Founded
1998
HQ
Employees
N/A
Website
Sectors
Financials (LTM)
EV
$2B
Yantai Dongcheng Financials
Yantai Dongcheng reported last 12-month revenue of $418M and EBITDA of $43M.
In the same LTM period, Yantai Dongcheng generated $43M in EBITDA and $44M in net income.
Revenue (LTM)
Yantai Dongcheng P&L
In the most recent fiscal year, Yantai Dongcheng reported revenue of $417M and EBITDA of $70M.
Yantai Dongcheng expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $418M | XXX | $417M | XXX | XXX | XXX |
| Gross Profit | — | XXX | $197M | XXX | XXX | XXX |
| Gross Margin | — | XXX | 47% | XXX | XXX | XXX |
| EBITDA | $43M | XXX | $70M | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | 17% | XXX | XXX | XXX |
| EBIT Margin | 9% | XXX | 14% | XXX | XXX | XXX |
| Net Profit | $44M | XXX | $27M | XXX | XXX | XXX |
| Net Margin | 11% | XXX | 6% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Yantai Dongcheng Stock Performance
Yantai Dongcheng has current market cap of $2B, and enterprise value of $2B.
Market Cap Evolution
Yantai Dongcheng's stock price is $1.92.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2B | $2B | 0.2% | XXX | XXX | XXX | $0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialYantai Dongcheng Valuation Multiples
Yantai Dongcheng trades at 3.7x EV/Revenue multiple, and 36.1x EV/EBITDA.
EV / Revenue (LTM)
Yantai Dongcheng Financial Valuation Multiples
As of March 21, 2026, Yantai Dongcheng has market cap of $2B and EV of $2B.
Equity research analysts estimate Yantai Dongcheng's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Yantai Dongcheng has a P/E ratio of 36.1x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV (current) | $2B | XXX | $2B | XXX | XXX | XXX |
| EV/Revenue | 3.7x | XXX | 3.7x | XXX | XXX | XXX |
| EV/EBITDA | 36.1x | XXX | 22.1x | XXX | XXX | XXX |
| EV/EBIT | 40.9x | XXX | 25.8x | XXX | XXX | XXX |
| EV/Gross Profit | — | XXX | 7.9x | XXX | XXX | XXX |
| P/E | 36.1x | XXX | 59.2x | XXX | XXX | XXX |
| EV/FCF | — | XXX | (63.0x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Yantai Dongcheng Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Yantai Dongcheng Margins & Growth Rates
Yantai Dongcheng's revenue in the last 12 month grew by 7%.
Yantai Dongcheng's rule of 40 is 17% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Yantai Dongcheng's rule of X is 27% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Yantai Dongcheng Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | (1%) | XXX | XXX | XXX |
| EBITDA Margin | 10% | XXX | 17% | XXX | XXX | XXX |
| EBITDA Growth | 97% | XXX | (52%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 17% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 27% | XXX | XXX | XXX |
| S&M Expenses to Revenue | — | XXX | 12% | XXX | XXX | XXX |
| G&A Expenses to Revenue | — | XXX | 3% | XXX | XXX | XXX |
| R&D Expenses to Revenue | — | XXX | 10% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 33% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Yantai Dongcheng Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Ardelyx | XXX | XXX | XXX | XXX | XXX | XXX |
| OneSource Specialty | XXX | XXX | XXX | XXX | XXX | XXX |
| Sawai Group Holdings | XXX | XXX | XXX | XXX | XXX | XXX |
| Biohaven | XXX | XXX | XXX | XXX | XXX | XXX |
| Nanobiotix | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Yantai Dongcheng M&A Activity
Yantai Dongcheng acquired XXX companies to date.
Last acquisition by Yantai Dongcheng was on XXXXXXXX, XXXXX. Yantai Dongcheng acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Yantai Dongcheng
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialYantai Dongcheng Investment Activity
Yantai Dongcheng invested in XXX companies to date.
Yantai Dongcheng made its latest investment on XXXXXXXX, XXXXX. Yantai Dongcheng invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Yantai Dongcheng
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Yantai Dongcheng
| When was Yantai Dongcheng founded? | Yantai Dongcheng was founded in 1998. |
| Where is Yantai Dongcheng headquartered? | Yantai Dongcheng is headquartered in China. |
| Is Yantai Dongcheng publicly listed? | Yes, Yantai Dongcheng is a public company listed on Shenzhen Stock Exchange. |
| What is the stock symbol of Yantai Dongcheng? | Yantai Dongcheng trades under 002675 ticker. |
| When did Yantai Dongcheng go public? | Yantai Dongcheng went public in 2012. |
| Who are competitors of Yantai Dongcheng? | Yantai Dongcheng main competitors are Ardelyx, OneSource Specialty, Sawai Group Holdings, Biohaven. |
| What is the current market cap of Yantai Dongcheng? | Yantai Dongcheng's current market cap is $2B. |
| What is the current revenue of Yantai Dongcheng? | Yantai Dongcheng's last 12 months revenue is $418M. |
| What is the current revenue growth of Yantai Dongcheng? | Yantai Dongcheng revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Yantai Dongcheng? | Current revenue multiple of Yantai Dongcheng is 3.7x. |
| Is Yantai Dongcheng profitable? | Yes, Yantai Dongcheng is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Yantai Dongcheng? | Yantai Dongcheng's last 12 months EBITDA is $43M. |
| What is Yantai Dongcheng's EBITDA margin? | Yantai Dongcheng's last 12 months EBITDA margin is 10%. |
| What is the current EV/EBITDA multiple of Yantai Dongcheng? | Current EBITDA multiple of Yantai Dongcheng is 36.1x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.